CONSHOHOCKEN, Pa., June 10, 2013 /PRNewswire/ -- ePharmaSolutions, a leading clinical services and eClinical solutions provider, has signed a deal with AstraZeneca Neuroscience Innovative Medicines (AZ NS iMed), to provide IT solutions that will enable the iMed to share and manage complex data on a common portal with clinical trial investigators and other external partners. The ePharmaSolutions integrated clinical trial portal will also feature an electronic trial master file (eTMF) solution and cloud technology for sharing documents securely. Initially, the ePharmaSolutions technology will be used to manage three separate neuroscience clinical trials.
AstraZeneca's Neuroscience iMed is a unique model in the pharma industry – a core of about 40 neuroscientists managing a portfolio of drug discovery and development projects solely with external partners. Since it was created just over a year ago, the iMed has strived to implement innovative technologies that enable it to work seamlessly – quickly and efficiently – with investigators, contract research organizations, academic researchers and regulatory authorities. "A key strategy for our business is crafted around relationship building and leveraging innovative solutions for data sharing with collaborators," said Steven Leventer, PhD, VP, AZ NS iMed. "The capabilities brought to the table by ePharmaSolutions are aimed at enabling the AZ NS iMed to ramp up our clinical trial sites more quickly and efficiently."
"We are very pleased to have been selected by the AZ NS iMed team for this collaboration," adds Lance Converse, founder and CEO of ePharmaSolutions. "Our integrated trial portal, document exchange and eTMF platform will play a pivotal role in supporting the study teams as well as the investigator sites."
ePharmaSolutions is a leading provider of eClinical solutions that help improve the way trial sites are selected, trained, activated and managed to exceed enrollment goals. ePharmaSolutions has won multiple Bio-IT World Award for best clinical trial technology and has activated and trained more than 300,000 clinical researchers in 130 countries for the top 20 pharmaceutical companies and CROs in the world. ePharmaSolutions is headquartered in Philadelphia with offices in Slough, UK. For more information, visit www.epharmasolutions.com or email email@example.com
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.